learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Re-Innovation in Clinical Trial Designs Based on Precision Therapy
Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
research Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
More precise, personalized therapies are needed for autoimmune diseases.
research Androgens Protect Against Apolipoprotein E4-Induced Cognitive Deficits
Androgens can help prevent memory problems caused by apoE4.
research Treatments for Alopecia Areata: A Network Meta-Analysis
The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
research Pathophysiology, Conventional Treatments, And Evidence-Based Herbal Remedies Of Hair Loss With A Systematic Review Of Controlled Clinical Trials
Herbal remedies may help with hair loss but need more research.
Community Join
5 / 87 resultscommunity Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days!
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Hope Medicine has a new CEO. Calling it now, he's probably going to axe HMI.
Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.